- Home
- AEE vs BIIB Comparison
AEE vs BIIB Comparison
Compare AEE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- BIIB
- Stock Information
- Founded
- AEE 1901
- BIIB 1978
- Country
- AEE United States
- BIIB United States
- Employees
- AEE N/A
- BIIB N/A
- Industry
- AEE Power Generation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- AEE Utilities
- BIIB Health Care
- Exchange
- AEE Nasdaq
- BIIB Nasdaq
- Market Cap
- AEE 27.3B
- BIIB 18.7B
- IPO Year
- AEE N/A
- BIIB 1991
- Fundamental
- Price
- AEE $98.54
- BIIB $143.68
- Analyst Decision
- AEE Buy
- BIIB Buy
- Analyst Count
- AEE 11
- BIIB 27
- Target Price
- AEE $102.82
- BIIB $188.09
- AVG Volume (30 Days)
- AEE 1.3M
- BIIB 1.5M
- Earning Date
- AEE 11-05-2025
- BIIB 10-29-2025
- Dividend Yield
- AEE 2.83%
- BIIB N/A
- EPS Growth
- AEE 2.91
- BIIB 31.67
- EPS
- AEE 4.55
- BIIB 10.45
- Revenue
- AEE $8,119,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- AEE $15.13
- BIIB $2.00
- Revenue Next Year
- AEE $6.13
- BIIB N/A
- P/E Ratio
- AEE $22.10
- BIIB $13.76
- Revenue Growth
- AEE 17.75
- BIIB 3.36
- 52 Week Low
- AEE $82.95
- BIIB $110.04
- 52 Week High
- AEE $104.10
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- AEE 40.65
- BIIB 58.49
- Support Level
- AEE $98.72
- BIIB $141.12
- Resistance Level
- AEE $101.17
- BIIB $150.28
- Average True Range (ATR)
- AEE 1.10
- BIIB 4.61
- MACD
- AEE -0.17
- BIIB 0.30
- Stochastic Oscillator
- AEE 1.08
- BIIB 64.82
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.